Nat Med by Herber, Donna L. et al.
Lipid accumulation and dendritic cell dysfunction in cancer
Donna L. Herber1,9, Wei Cao1,9, Yulia Nefedova1, Sergey V. Novitskiy1, Srinivas Nagaraj1,
Vladimir A. Tyurin2, Alex Corzo1, Hyun Il Cho1, Esteban Celis1,3, Briana Lennox1, Stella C.
Knight4, Tapan Padhya5, Thomas V. McCaffrey5, Judith C. McCaffrey5, Scott Antonia6,
Mayer Fishman7, Robert L. Ferris8, Valerian E. Kagan2, and Dmitry I. Gabrilovich1,3,10
Donna L. Herber: dherber@research.usf.edu; Wei Cao: wei.cao@moffitt.org
1 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2 Center for Free Radical and Antioxidant Health, Department of Environmental Health, University
of Pittsburgh, Pittsburgh, PA
3 Department of Molecular Medicine, University of South Florida, Tampa, FL
4 Imperial College London, London, UK
5 Department of Otolaryngology, University of South Florida, Tampa, FL
6 Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa,
FL
7 Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL
8 Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA
Abstract
Professional antigen presenting cells, dendritic cells (DC) are responsible for initiation and
maintenance of immune responses. Here, we report that a substantial proportion of DCs in tumor-
bearing mice and cancer patients have increased levels of triglycerides. Lipid accumulation in DCs
was caused by increased uptake of extracellular lipids due to up-regulation of scavenger receptor
A. DCs with high lipid content were not able to effectively stimulate allogeneic T cells or present
tumor-associated antigens. DCs with high and normal lipid levels did not differ in expression of
MHC and co-stimulatory molecules. However, lipid-laden DCs had reduced capacity to process
antigens. Pharmacological normalization of lipid levels in DCs with an inhibitor of acetyl-CoA
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carboxylase restored the functional activity of DCs and substantially enhanced the effects of a
cancer vaccine. These findings support the regulation of immune responses in cancer by
manipulation of lipid levels in DCs.
Introduction
DCs are antigen presenting cells specializing in acquisition, processing, and presentation of
antigens to T cells. The defective function of DCs in cancer contributes greatly to tumor
escape (rev. in 1,2). During investigation of effect of tumor-derived factors on DC
differentiation, we unexpectedly observed accumulation of lipids in DCs generated in the
presence of tumor cell conditioned medium (Supplementary Fig. 1). These findings
prompted us to investigate the potential role of lipid accumulation in DC function in cancer.
Lipids represent a diverse group of low molecular weight molecules. Most lipid molecules
contain fatty acid moieties3. Lipids are an important energy resource and a major structural
component of the membrane matrix. Signaling functions of fatty acids are now considered a
core component of the network, regulating different cells (rev in. 4).
The factors affecting storage, uptake and metabolism of different fatty acids in DC may
impact the function of the immune system5. A number of studies have shown the negative
effect of dietary lipids on DC function6–14 (see supplementary material). These data
indicate that lipids could be an important factor regulating DC function. However, their
exact role in DC activity remains unclear. There is very little information regarding the
biological or clinical significance of lipid accumulation in DCs in cancer. Here, we report
our novel finding that accumulation of lipids in DCs is not only a consistent phenomenon
found in tumor-bearing hosts, but also has a profound effect on DC function.
Results
Lipid accumulation in DCs
To evaluate the level of lipids in DCs we used the lipophilic fluorescent dye Bodipy
493/503. CD11c+ DCs isolated from spleens of mice bearing EL-4 tumor displayed higher
fluorescence than their control counterparts (Fig. 1a). Using flow cytometry we detected two
populations of CD11c+ DCs in tumor-bearing (TB) mice. One population termed DCs with
normal lipid content (DC-NL) representing 30–50% of cells had a similar level of
fluorescence to that in control DCs. The other population (50–70% of cells) referred to as
DCs with high lipid content (DC-HL) had fluorescence higher than that in control DCs (Fig.
1b). The level of lipids in spleen DCs was elevated in all 4 tested tumor models in C56BL/6
and BALB/c mice as compared with DCs from control mice (Fig. 1c) and it increased with
tumor progression (Fig. 1d). Increased lipid levels were observed in CD11c+CD8+ DCs and
CD11c+CD11b+B220− conventional DCs (cDC) but not in CD11c+CD11b−B220+
plasmacytoid DCs (pDC) (Fig. 1e). DCs isolated from tumors had higher levels of lipids
than DCs from blood and lymph nodes (LN) (Fig. 1f). DCs from the LN, bone marrow
(BM), and blood from TB mice had higher levels of lipids than DCs from control mice (Fig.
1g). The lipid content was equally elevated in DCs from tumor-draining and distant LNs
(Fig. 1h).
To evaluate the nature of these lipids, CD11c+ DCs were isolated from spleens of naïve and
TB mice. Total lipids were extracted and analyzed by high performance thin layer
chromatography (HPTLC), and electrospray ionization mass spectroscopy (ESI-MS). DCs
from TB mice showed dramatically higher levels of triglycerides (triacylglycerol, TAG)
than cells from naïve mice. In contrast, no differences were found in serum TAG level
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between naive and TB mice (Fig. 1i). Most of the molecular species of TAG were elevated
in DCs from TB mice as compared with their control counterparts (Supplementary Fig. 2a)
and no differences were found in the profile of major molecular species of TAG between
serum samples (data not shown). In contrast to TAG no changes were observed in the levels
of cholesteryl-esters and phospholipids (Supplementary Fig. 2b,c).
Lipid levels were evaluated in DCs from 12 individuals with head and neck cancer (HNC).
Peripheral blood (PB), draining LN, and tumor tissues were collected during surgery. DCs
were identified as Lineage−CD4+ cells15 (Fig. 2a). DCs from PB of persons with cancer
showed significantly higher levels of lipids than PB DCs from the healthy individuals. The
lipid level in DCs from LN and tumors was considerably higher than that in DCs from PB
(Fig. 2b). Similar findings were obtained in the cohorts of patients with non-small lung
cancer and renal cell cancer (Fig. 2c). In separate experiments we found that LN DCs from
persons with HNC contained significantly higher level of lipids than LN DCs from
individuals with benign tumors (Fig. 2d). Thus, these data strongly corroborate those
obtained from mouse tumor models.
Mechanism of lipid accumulation in DCs
To study the mechanisms of lipid accumulation in DCs these cells were generated in vitro
from BM progenitors (BMP) using GM-CSF and IL-4. Short 24 h incubation of DCs with
tumor explant supernatants (TES) resulted in more than 3-fold increase in the lipid level
(Fig. 3a). Analysis of lipid content by ESI-MS revealed that DCs generated in the presence
of TES had almost 6-fold higher level of TAG than DCs generated in control culture
medium (CM) (Fig. 3b). There was an increase in the level of all molecular species of TAG
but no changes were observed in the level of phospholipids and cholesteryl-esters in these
DCs (Supplementary Fig. 3). The total level of TAG in CT-26 TES was > 4 times higher
than in CM (Fig. 3b). Despite variability in TAG level in TES obtained from different tumor
cell lines they all caused comparable up-regulation of lipids in DCs (Supplementary Fig. 4).
To directly evaluate fatty acid uptake, DCs cultured for 24 h with TES were incubated with
fluorescently labeled palmitic fatty acid for 30 min at 37°C. DCs pre-incubated with TES
had dramatically higher uptake of fatty acid than DCs incubated in control medium (Fig.
3c). Overnight incubation of DCs from spleens of TB mice in serum-free medium
eliminated elevated level of lipids in these cells, while not affecting the level of lipids in
control DCs (data not shown). These data suggested that increased uptake of lipids may be
the major mechanism of lipid accumulation by DCs.
We then investigated why DCs from tumor-bearing hosts have higher lipid uptake than in
controls. Scavenger receptors (SR) play an important role in intracellular transport of lipids.
Currently little is known about changes in their expression on DCs from tumor-bearing
hosts. Therefore, we evaluated the level of four major SR (Macrophage scavenger receptor,
Msr1 (CD204), Cd36 (Srb), Cd68, and Marco). EL-4 TES caused significant up-regulation
of the expression of Msr1 in DCs (Fig. 3d). This was associated with increased expression of
this receptor on the surface of DCs (Fig. 3e). A similar effect was observed with TES from
CT-26 and B16F10 tumors (data not shown). Msr1 was the only SR significantly elevated in
DCs from TB mice (Fig. 3f). cDC from TB mice had 3-fold higher levels of Msr1 than their
control counterparts. In contrast, no up-regulation of Sra was observed in pDC (Fig. 3g). No
differences were found in the expression of Msr1 between DCs from naïve mice and DC-NL
from TB mice. However, DC-HL expressed substantially higher levels of Msr1 (Fig. 3h).
Similar results were obtained in experiments in vitro (Supplementary Fig. 5a). Elevated
Msr1 expression was detected in DCs from all tested sites of TB mice and the level of Msr1
in DCs isolated from tumor was 20–50-fold higher than in other sites (Supplementary Fig.
5b). Thus, the pattern of Msr1 expression was similar to that of lipids and suggested that up-
regulation of this receptor might be involved in lipid accumulation in DCs.
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To directly test this hypothesis we used fucoidan, a soluble ligand which prevents binding of
natural ligands to SRs. Fucoidan did not affect DC viability but completely abrogated the
effect of CT-26 TES on lipid accumulation (data not shown). Pre-incubation of DCs with
neutralizing antibodies to Msr1 completely abrogated the effect of TES on lipid
accumulation, whereas Cd36-specific antibody had little effect (Fig. 3i). We generated DCs
from BMP of wild-type and Msr1−/− C57BL/6 mice (CD45.2+). These DCs were transferred
i.v. into sub-lethally irradiated congenic (CD45.1+) tumor-free or EL-4 TB recipients. Two
days later the level of lipids was evaluated in CD45.2+ donor’s cells isolated from recipient
spleens. Donor’s DCs in TB recipients demonstrated significantly higher levels of lipids
than cells in tumor-free recipients. In contrast, DCs generated from Msr1−/− mice failed to
accumulate lipid after transfer to TB recipients (Fig. 3j). Analysis of TAG content by ESI-
MS showed that in contrast to wild-type DCs Msr1 deficient DCs did not accumulate TAG
during the culture with CT-26 TES (Supplementary Fig. 6). Taken together these data
indicate that up-regulation of Msr1 plays a major role in accumulation of lipids in DCs in
cancer.
Functional activity of lipid laden DCs
To investigate whether lipid accumulation in DCs has functional consequences, DC-HL and
DC-NL from spleens of control and CT26 TB mice were sorted using the gates set around
lipid levels in control DCs (Fig. 4a) and then used for stimulation of allogeneic T cells. DCs
from control mice and DC-NL from TB mice had similar effects on allogeneic T-cell
proliferation, whereas DC-HL from TB mice had substantially lower stimulatory activity
(Fig. 4b). Similar results were obtained with in vitro generated DCs cultured for 48 h with
TES (Fig. 4c).
Msr1-specific antibody abrogated the negative effects of TES on DC function (Fig. 4d). TES
inhibited ability of DCs generated from wild-type BMP to stimulate allogeneic T cells,
whereas it did not affect this function of DCs generated from Msr1−/− BMP (Fig. 4e).
DC-NL and DC-HL isolated from EL-4 TB mice equally stimulated responses of transgenic
CD4+ or CD8+ T cells to OVA-derived specific peptides (Fig. 4f,g). Different results were
obtained when DCs were loaded overnight with soluble protein (OVA). CD11c+ DCs from
TB mice had reduced ability to stimulate proliferation of OVA-specific CD4+ T cells (Fig.
4h). DC-NL from TB mice and control DCs showed similar activity in stimulation of OVA-
specific CD4+ (Fig. 4i) and CD8+ (Fig. 4j) T cells, whereas DC-HL induced a substantially
lower response. Thus DC-HL had substantially reduced capacity to stimulate T cells when it
required processing of antigen.
Lipid-laden DCs have reduced capacity to process and present antigen
We compared the phenotype of CD11c+ DCs with normal and high lipid content from TB
mice. We found no differences in the proportion of DCs expressing markers of macrophages
or granulocytes (F4/80 and Gr-1) as well as in the level of expression of these markers
between DC-NL and DC-HL (Supplementary Fig. 7a). Although DCs from TB mice had
significantly lower levels of MHC class I, II, and co-stimulatory molecules (CD40, CD86,
and CD80) than DCs from naive mice, no differences between DC-NL and DC-HL were
found (Supplementary Fig. 7b).
One possible explanation for these results could be a decreased uptake of soluble proteins by
DC-HL. To test this possibility DCs generated from BMP in the presence of TES were
incubated with fluorescently labeled OVA-APC. DC-NL had the same levels of OVA
uptake as control DCs, whereas DC-HL showed significantly higher levels of OVA-APC
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(Fig. 5a). Similar results were obtained in vivo after injection of EL-4 TB mice i.p. with
OVA-APC (Fig. 5b). Thus, DC-HL internalized more soluble protein than DC-NL.
To assess the ability of DCs to process antigen we used BSA-DQ, a self-quenching
conjugate of bovine serum albumin that exhibits fluorescence upon proteolytic degradation.
To normalize for increased protein uptake by DC-HL we used the ratio of OVA-FITC and
BSA-DQ fluorescence after loading DCs with these proteins. DCs isolated from TB mice or
cultured with TES had substantially lower BSA-DQ/OVA-FITC ratio than DCs from control
mice or cells cultured in control medium (Fig. 5c). This effect was observed at all tested
time points (Fig. 5d). To verify these observations we used 25-d1.16 antibody that
recognizes the OVA derived epitope bound to H2Kb (pMHC). CD11c+ DCs isolated from
the spleens of EL-4 TB or control mice were loaded with OVA overnight and then stained
with 25–D1.16 antibody. The binding of this antibody to DCs from TB mice was lower than
to DCs from control mice (Fig. 5e). DCs generated from BMP in the presence of TES were
loaded with OVA and then stained with Bodipy and pMHC antibody. DC-HL had
considerably lower binding of the antibody than DC-NL (Fig. 5f).
We then addressed whether DC-NL and DC-HL differ in the presentation of tumor-
associated antigen. Draining LN were isolated from mice with EG-7 tumors that express
OVA and the level of pMHC in LN DCs was evaluated. DC-HL had lower expression of
pMHC than DC-NL from the same mice (Fig. 5g). DC-HL and DC-NL cells were sorted
from LN of EG-7 TB mice and cultured with OVA-specific OT-II T cells. DC-HL induced a
lower response of OT-II T cells than DC-NL (Fig. 5h). In contrast, no difference in the T-
cell response between DC-HL and DC-NL was seen when DCs were loaded with specific
peptide prior to incubation with T-cells (Fig. 5i). Taken together these data indicate that DC-
HL may have defects in processing of tumor-associated proteins.
Effects of regulation of lipid levels on DC function in cancer
To identify the potential role of lipid accumulation in abnormal DC function in cancer we
tried to regulate fatty acid levels using an inhibitor of acetyl-CoA carboxylase (ACC), 5-
(tetradecycloxy)-2-furoic acid (TOFA)16. Since TAG undergo rapid degradation in the
cells, the maintenance of their high level requires active fatty acid synthesis. We
hypothesized that when synthesis is blocked, then cells will not be able to sustain high level
of TAG even if lipid uptake is increased. When HPCs were cultured with TES in the
presence of TOFA, it prevented the accumulation of lipids in DCs (Fig. 6a) without
affecting the viability or causing up-regulation of co-stimulatory molecules or MHC class II
(data not shown). Treatment with TOFA significantly improved the ability of DCs generated
in the presence of TES to stimulate allogeneic T cells (Fig. 6b). To test the effect of TOFA
in vivo, EL-4 TB mice were treated for 2 weeks with TOFA filled osmotic pumps. At the
selected dose (1μg/hr) TOFA did not affect the number of DCs and did not cause changes in
the expression of MHC class II or co-stimulatory molecules (data not shown) but it reduced
the presence of lipid-laden DCs (Fig. 6c) and restored the ability of DCs to stimulate
allogeneic T cells (Fig. 6d).
To test the possibility that TOFA might improve antitumor response EL-4 TB mice were
immunized with DCs transduced with Ad-survivin (Ad-surv)17. Vaccine or TOFA alone
had little effect on growth of established tumor. Combination of TOFA with vaccine
resulted in significant (p=0.041) decrease in tumor growth (Fig. 6e). In a different
experimental system, C57BL/6 mice were injected s.c. with B16F10 melanoma cells and
then vaccinated with the peptide derived from melanoma specific protein - tyrosinase 1.
TOFA alone did not affect tumor growth. Vaccine alone caused a temporary decrease in
tumor growth, but the combination of TOFA with vaccine provided for significantly
(p<0.01) more potent antitumor effects (Fig. 6f).
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This study has demonstrated that a substantial proportion of DCs in TB hosts have increased
amount of lipids, specifically triglycerides. These results were obtained using different
methods of lipid detection in several tumor models and also in cancer patients across several
diagnoses. These findings were reproduced by using conditioned medium from tumor
explants indicating that tumor-derived factors were responsible for the observed
phenomenon. In this study we have tried to address two main questions: what is the
mechanism of lipid accumulation in DCs and whether it has any functional consequences for
these cells.
Accumulation of lipids could be due to increased synthesis of fatty acids or because of
increased lipid uptake from plasma. Our data suggested that the second explanation is more
likely (Fig 3). Scavenger receptors represent a major route in acquiring fatty acids by DCs
and macrophages 18–20 (see supplementary material). Our results indicate that DCs from
TB mice had preferential up-regulation of Msr1. This was consistent with the data
demonstrating increased expression of Sra on macrophages during co-culture with ovarian
tumor cells21. DCs isolated from tumor tissues had substantially higher levels of Msr1 than
cells isolated from spleens or LN, which paralleled the results with lipid level in these cells.
Association between the expression of this receptor and lipid levels in DCs was further
evident in the analysis of DC subsets. In our study accumulation of lipids and up-regulation
of Msr1 was observed in cDC but not in pDCs. This was consistent with the results of a
study that demonstrated that in contrast to cDCs, expression of Msr1 was not detectable in
mouse and human pDCs22. Our experiments with blocking of Msr1 with the soluble SR
ligand fucoidan23 and specific antibody, as well as experiments with Msr1−/− mice, have
demonstrated that up-regulation of Sra was primarily responsible for increased uptake of
exogenous lipids by DCs. It is likely that fatty acids are transferred to DCs in the form of
modified lipoproteins. Different lipoprotein modifications have been described in cancer and
those lipoproteins are likely abundant in tumor-bearing hosts24,25. It is likely that
accumulation of lipids by DCs in vitro and in vivo is due to the presence of tumor-derived
factors that up-regulate the expression of Sra on DCs, which enable these cells to pick up
modified lipoproteins from serum. The nature of those factors remain unclear and require
further investigations (see supplementary material).
In our studies lipid-laden DCs had a profound defect in ability to process and present soluble
antigens. One possible explanation could be that lipid-laden DCs are immature cells, which
are effective in picking up soluble proteins but have poor ability to present antigens.
However, the fact that DC-HL and DC-NL expressed similar levels of MHC class II, and co-
stimulatory molecules as well as the fact that peptide-loaded DC-HL and DC-NL stimulated
specific T-cells equally well argues against this possibility. The molecular mechanisms by
which fatty acids could affect antigen processing are currently not clear.
The results of the experiments with inhibition of fatty acid synthesis in TB mice
demonstrated that this might improve DC function in TB host and antitumor immune




Several cohorts of human subjects have been analyzed. All individuals signed University of
South Florida IRB approved consent forms. The description of cohorts and processing of
samples is provided in supplementary materials.
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Mice and tumor models
Female Balb/c or C57BL/6 mice were obtained from the National Cancer Institute. Tumor
cell lines included CT-26 (on Balb/c mice) and MC38 (on C57BL/6 mice) colon
carcinomas, B16F10 melanoma, EL4 lymphoma (both on C57BL/6 mice), and DA3 breast
carcinoma (on Balb/c mice) described elsewhere26. All cells were maintained in Dulbecco’s
modified eagle’s medium (Invitrogen Corp.) plus 10% fetal bovine serum (FBS, Sigma-
Aldrich) at 37°C, 5% CO2. Tumors were injected subcutaneously (s.c.) at 5×105 cells per
mouse and allowed to grow 3–4 weeks or until tumors reached 2 cm in diameter. OT-I TCR-
transgenic mice (C57Bl/6-Tg(TCRaTCRb)1100mjb) have a T cell receptor that recognizes
OVA residues 257–264 in the context of H2Kb. OT-II transgenic mice (C57BL/6-
Tg(TcraTcrb)425Cbn/J) express the mouse T cell receptor that is specific for OVA323–339 in
the context of I-Ab. These mice, as well as Msr1−/− mice (B6.Cg-Msr1tm1Csk/J), were
obtained from Jackson Laboratories. Mice were housed and euthanized according to
University of South Florida IACUC guidelines.
The following peptides were used in the studies: OT-I specific peptide – SIINFEKL, OT-II
specific peptide – ISQAVHAAHAEINEAGR, control non-specific peptide – RAHYNIVTF.
All peptides were obtained from the American Peptide Company (Vista, CA).
Generation and isolation of dendritic cells
DCs were generated from BM progenitor cells using culture with 10 ng/mL recombinant
mouse GM-CSF (Invitrogen Corp), and 10 ng/mL interleukin 4 (IL-4) (R&D Systems) as
described previously27.
Preparation of tumor conditioned medium
Tumor explants were prepared from freshly isolated subcutaneous tumors (see
supplementary material).
Analysis of cell phenotype by flow cytometry
Cells were incubated with fluorescently labeled antibodies directed against cell surface
markers. All antibodies were purchased from either BD Pharmingen or Serotec. 25-d1.16
antibody was obtained from eBioscience. Cell surface labeling was performed on ice for 30
min. Cells were then washed and re-suspended in 500 μL of Bodipy 493/503 at 0.5μg/mL in
PBS. Cells were stained for 15 min at room temperature before the analysis. All experiments
using Bodipy 493/503 staining were performed on LSRII or FACSAria (BD). For cell sorts,
the gates defining normal lipid levels for discrimination of DC-NL vs. DC-HL in TB hosts
were set using the fluorescence of control DCs as the background. A low pressure sort was
performed using the BD FacsAria cell sorter with a 100 μm nozzle.
Lipid profiling by thin layer chromatography
See supplementary material.
Loading of DCs with fatty acid
DCs were incubated with fluorescently labeled (Bodipy FL) palmitic fatty acid (Molecular
Probes) at 37°C for 15–30 min. Controls consisted of unloaded DCs or DCs loaded on ice.
5×106 DCs were re-suspended in 500μL of 10μg/mL fatty acid.
Functional assays
T cell proliferation was measured using a mixed leukocyte reaction or antigen specific
proliferation. DCs were isolated as described above. T cells were isolated using R&D
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Systems Mouse T cell Enrichment columns, according to the manufacturer’s protocol (R&D
Systems). T cells were plated at 105 T cells per well. DCs and T cells were mixed at
different ratios. Antigen specific T cell proliferation was assessed with either OT-I or OT-II
transgenic T cells. Isolated DCs (5×106 cells/mL) were incubated with 10 μg/mL of specific
or control peptides for 90 minutes. Peptide loaded DCs were then washed and mixed with
appropriate transgenic T cells at different ratios. Cells were incubated for 72 h. 3[H]-
thymidine was then added at 1μCi per 200uL of cells per well for an additional 18 hours of
incubation followed by cell harvesting and radioactivity count using a liquid scintillation
counter.
Vaccination of mice
C57BL/6 mice were injected s.c. with 5×105 EL-4 or 3×105 B16F10 tumor cells. Four-five
days later EL-4 TB mice were immunized with s.c. injection of 5×105 DCs transduced Ad-
surv and vaccination was repeated twice with weekly interval. B16F10 TB mice were
vaccinated twice weekly i.v. with a mixture of 150 μg optimized Trp1455–463/9M
(TAPDNLGYM) peptide and two Toll-like receptor ligands (TLR-L) [50 μg poly-IC, 100
μg CpG-1826]. CpG-1826 was prepared by the Mayo Clinic Molecular Core Facility. Poly-
IC (Hiltonol, a clinical grade stabilized formulation containing poly-L-lysine and
carboxymethyl cellulose) was provided by Dr. Andres Salazar (Oncovir, Inc., Washington,
DC).
Quantitative real-time polymerase chain reaction (qRT-PCR)
PCR was performed as described earlier 28 and details are provided in supplementary
material.
Statistical Analysis
Statistical analysis was performed using 2-tailed Mann-Whitney or Wilcoxon non-
parametric tests with significance determined at p<0.05. The geometric mean is reported for
all fluorescence results. Tumor measurements were analyzed using two-way ANOVA test
with Bonferroni post-test. All statistical analyses were performed using GraphPad PRISM 5
software (GraphPad Software, Inc. La Jolla, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Lipid levels in DCs from TB mice
a. Staining of CD11c+ from the spleens of naïve and EL-4 TB mice with Bodipy 493/503.
10μm scale bar shown. b. A typical example of the analysis of lipid level in CD11c+ DCs
from spleens of control (red) or EL-4 TB mice (blue). c. Cumulative results of lipid staining
of splenocytes from different tumor models. Geomean fluorescence intensity (MFI) of
Bodipy 493/503 in CD11c+ DCs was measured. Each group includes 4-8 mice. Control and
TB mice were evaluated in parallel in each experiment. d. Proportion of DCs with high lipid
content in spleens during progression of CT-26 tumors. Each time point included 3 mice.
Mean ± SD are shown. e. Lipid levels in different populations of DCs from the spleens of
control or EL-4 TB mice. pDC –plasmacytoid DCs; cDC-conventional DCs. Each group had
3 mice. f. Lipid levels in CD11c+ DCs from different organs of CT-26 TB mice collected on
week 3 after tumor inoculation (tumor size - 1.5 cm in diameter). Mean ±SD from 4 mice
are shown. g. Lipid levels in CD11c+ DCs from naïve or CT-26 TB mice collected on week
3 after tumor inoculation. Mean ±SD from 3 mice per group are shown. h. Lipid level in
CD11c+ DCs from draining (inguinal) and distant (contra-lateral axillary) LNs in EL-4
tumor-bearing mice. Three experiments with the same results were performed. i. The
amount of triglycerides (TAG) per 106 CD11c+ DCs isolated from spleens of naïve BALB/c
mice and CT-26 TB mice and in sera of TB mice. Each group included 3 mice. * -
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statistically significant differences (p<0.05) between values in DCs from control and TB
mice.
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Figure 2. Lipid level in DCs from cancer patients
a. Typical example of Bodipy staining of DCs from cancer patient. b. Cumulative results of
lipid levels in DCs from patients with head and neck cancer. P values between the levels of
lipids in blood DCs from control donors are shown; n = the number of samples analyzed. c.
Lipid levels in peripheral blood DCs from patients with non-small lung cancer (NSCLC) and
renal cell cancer (RCC). P values between the levels of lipids in blood DCs from control
donors are shown n = the number of samples analyzed. d. Lipid levels in DCs from lymph
nodes obtained from patients with head and neck cancer and benign tumors. P values
between the levels of lipids in DCs from cancer patients and patients with benign tumors.
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Figure 3. The mechanism of lipid accumulation in DCs
a. Lipid level in DCs generated from enriched BM HPC and cultured in the presence of
different concentrations of TES for indicated period of time. b. The total level of TAG using
ESI-MS in CD11c+ DCs generated from BM HPC in the presence of 20% TES.
Measurements were performed in triplicate. c. Uptake of fluorescently labeled C16 fatty
acid by DCs generated from BM HPC and cultured for 24 hr with control medium or TES.
The left panel is a typical example of staining after 30 min incubation with C16 fatty acid.
The right panel shows cumulative results of 3 performed experiments (Mean±SD). Ice –
cells incubated with fatty acid at 4°C; 37°C – cells incubate with fatty acid at 37°C. d. Gene
expression of indicated SR in DCs cultured for 48 h with control medium or TES. Samples
were evaluated in triplicate by qRT-PCR and the results were normalized to the level of
expression of β-actin. The fold changes between DCs generated with TES and control were
calculated. The results of from 3 performed experiments are shown. e. Expression of Msr1
on the surface of DCs cultured with control medium (CM) or TES. IC – isotype control. The
typical examples of three performed experiments are shown. f. Gene expression of indicated
scavenger receptors in DCs from naïve and EL-4 TB mice by qRT-PCR. The results were
normalized to the level of expression of β-actin. Fold changes between EL-4 TB DCs and
control DCs were calculated. The results of 3 performed experiments are shown. g.
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Expression of MSR1 within the population of conventional (cDC) or plasmacytoid (pDC)
spleen DCs from naïve and EL-4 TB mice. Shaded histogram – isotype control; grey line –
naïve mice, bold black line – TB mice. h. Expression of MSR1 in spleen DCs with normal
lipid content (TB-NL) and high lipid content (TB-HL) from EL-4 TB mice. Control – DCs
from control mice. Mean ± SD of 4 performed experiments are shown. * - statistically
significant differences (p<0.05) from values in control DCs. Fluorescence of cells labeled
with isotype control IgG was less than 20 in all samples. i. Lipid level in DCs generated in
vitro and cultured for 3 days with TES in the presence of control IgG, or indicated
antibodies against scavenger receptors. Mean ± SD from three experiments is shown. * -
statistically significant differences (p<0.05) from values in control DCs. j. Lipid levels in
DCs generated from enriched BM HPC of wild-type (WT) or MSR1 knockout (KO) C57BL/
6 mice and transferred i.v. into sub-lethally irradiated congenic tumor-free (control) or EL-4
TB (TB) recipients. Lipids were measured in donor’s cells isolated from spleens of
recipients two days after the transfer. Each group includes 4–8 mice. Geometric mean of
fluorescence is shown. P values between control and TB mice were calculated using two-
tailed Mann-Whitney test.
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Figure 4. Defective functional activity of DCs with high lipid content
a,b. Stimulation of allogeneic T cell proliferation by DCs with different lipid content
isolated from CT-26 TB mice. a. Examples of gates set for the sort of CD11c+ cells. Blue-
naïve mouse, red–TB mouse. b. Stimulation of proliferation of allogeneic T cells by sorted
DCs with high and low lipid content. Typical results of 4 performed experiments are shown.
T cells alone had 3[H]-thymidine uptake of less than 500 CPM. c. Stimulation of allogeneic
T cell proliferation by DCs generated from enriched BM HPC from naïve BALB/c mice,
exposed for 2 days to CT-26 TES and sorted for DC-HL (red) or DC-NL (green) and
compared to DCs cultured in control medium (blue). Three experiments with similar results
were performed. T cells alone had 3[H]-thymidine uptake of less than 200 CPM. d. DCs
were generated from HPC of C57BL/6 mice and cultured for 3 days with EL-4 TES in the
presence of control IgG or anti-MSR1 antibody. After that time cells were cultured in
Herber et al. Page 16













triplicate with allogeneic T cells at indicated ratios and cell proliferation was evaluated
by 3[H]-thymidine uptake. T cells alone had 3[H]-thymidine uptake of less than 500 CPM. e.
DCs generated from BM HPC of wild-type and MSR1 KO mice in the presence of TES as
described in Fig. 3j were used as stimulators in an allogeneic mixed leukocyte reaction. T-
cell proliferation was measured by 3[H]-thymidine uptake. Two independent experiments
were performed in triplicate. The values of T-cell proliferation induced by wild-type or
MSR1-deifient DCs generated without the presence of TES were set as 100%. Values of T-
cell proliferation induced by DCs generated in the presence of TES are presented as
percentage from control level. f,g. DCs with high and normal lipid content were sorted from
spleens of naïve and EL-4 TB mice and incubated at indicated ratios with T cells from OT-II
(f) or OT-I (g) transgenic mice in the presence of 10 μg/ml of specific peptides. T cell
proliferation was measured in triplicate by 3[H]-thymidine uptake. In the absence of
peptides 3[H]-thymidine uptake in all samples was less than 5×103 CPM. Three experiments
with the same results were performed. h. CD11c+ DCs isolated from spleens of naïve and
EL-4 TB mice were cultured overnight with 1 mg/ml OVA or in medium alone and then
used to stimulate T cells from OT-II transgenic mice. T cell proliferation was measured in
triplicate by 3[H]-thymidine uptake. i.j. DCs with high and normal lipid content were sorted
from the spleens of EL-4 TB mice and incubated overnight with 1 mg/ml OVA. Cells were
used to stimulate T cells from OT-II (i) and OT-I (j) transgenic mice. T-cell proliferation
was measured in triplicate using 3[H]-thymidine uptake. Two experiments with similar
results were performed.
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Figure 5. Antigen processing in lipid-laden DCs
a. One-hour uptake of OVA-APC by DCs generated from HPC in the presence of TES. The
level of APC fluorescence was evaluated within the DC-NL and DC-HL populations. Mean
±SD of three performed experiments are shown. * - statistically significant differences
(p<0.05) from control DCs. b. Uptake of OVA-APC by DCs from EL-4 TB mice 2 h after
i.p. injection of 100 μg of OVA-APC. Mean±SD of three mice per group is shown. c. DCs
were either generated in vitro and then cultured for 48 h in control medium or TES, or
isolated directly from spleens of naïve or EL-4 tumor-bearing (TB) mice. Cells were loaded
with either 1 mg/ml DQ-BSA or 10 mg/ml FITC-OVA. DQ-BSA/FITC-OVA ratio was
calculated within CD11c+ DCs after 1 h incubation. DQ-BSA/FITC-OVA ratio in control
samples was expressed as 100%. Two experiments with the same results were performed. d.
DCs generated in vitro as described above were loaded with DQ-BSA or FITC-OVA and
incubated for the indicated time. Fluorescence in CD11c+ DCs was evaluated as described
above. e. CD11c+ DCs were isolated from spleens of tumor-free and EL-4 tumor-bearing
mice and loaded overnight with 1 mg/ml OVA. Cells were then stained with APC
conjugated 25-d1.16 antibody. A typical result of one experiment out of 4 performed is
shown. f. DCs were generated from progenitors in the presence of EL-4 TES and then
loaded overnight with 1 mg/ml OVA. DCs were stained with Bodipy 493/503 and labeled
with 25-d1.16 antibody. DCs with high and normal lipid content were analyzed. The mean
fluorescence of cells stained with isotype control Ig was less than 20. * - statistically
significant differences (p<0.05) between DC-NL and DC-HL. Cumulative results of 3
independent experiments are shown. g. Binding of 25-d1.16 antibody to DC-NL and DC-
HL DCs from LN cells of EG-7 TB mice. The fluorescence of cells stained with isotype
control Ig was less than 20. h.i. DCs with high and normal lipid content were sorted from
LN of EG-7 TB mice and incubated with T cells isolated from OT-II transgenic mice in the
absence of (h) or in the presence of 10 μg/ml of OT-II specific peptide (i). T cell
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proliferation was measured in triplicate by 3[H]-thymidine uptake. Two experiments with
the same results were performed.
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Figure 6. Effects of pharmacological regulation of lipid levels on DC function in cancer
a. Lipid levels in DCs generated in vitro from HPC and cultured for 3 days with EL-4 TES
in the presence of 5 μg/mL TOFA. b. Proliferation of allogeneic (BALB/c) T cells cultured
with DCs generated from HPC in the presence of TES and TOFA. Proliferation was
measured in triplicate by 3[H]-thymidine uptake. T cells alone had 3[H]-thymidine uptake of
less than 103 CPM. c. Tumor-free (control) and EL-4 TB (TB) mice were treated for 2
weeks with TOFA using osmotic pumps (rate of release 1 μg/hr). Pumps filled with water
were used as controls. The proportion of DCs with high lipid content was calculated. For
each experiment 2 mice per group were used. Experiments were performed twice and the
Mean±SD of the cumulative results is shown. * - statistically significant differences between
TB and TB+TOFA groups. d. CD11c+ DCs isolated from the spleen of mice as described in
Fig. 6c were incubated with allogeneic T cells and cell proliferation measured in triplicate
by 3[H]-thymidine uptake. T cells alone had 3[H]-thymidine uptake of less than 103 CPM. e.
EL-4 tumor was established in C57BL/6 mice.. Mice (5 mice per group) were immunized
with 5×105 DCs transduced Ad-surv 4 days after tumor inoculation.. Vaccination was
repeated twice at weekly intervals. Fourteen day osmotic pumps (Alzet, Cupertino, CA)
(1μg/hr rate release) containing water or TOFA were implanted on day 14 after tumor cell
injection. Tumor size was monitored and is presented as Mean ± SD per group. f. B16F10
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tumor was established in C57BL/6 mice. Five days after tumor inoculation mice (8 mice per
group) were immunized with a mixture of specific peptide and two Toll-like receptor ligands
(TLR-L) [50 μg poly-IC, 100 μg CpG-1826]. Fourteen day osmotic pumps (1μg/hr rate
release) filled with PBS were used in combination with lynch coil polyethylene tubing
containing water or TOFA. Pumps were implanted on day 14 after tumor cell injection.
Tumor size was monitored and results are presented as the mean tumor size (area in mm2) ±
SD for every treatment group at various time points until the termination of the experiment.
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